• Explore /
  • Poster
  • / TAS-118 (S-1 plus leucovorin) versus S-1 in gemcitabine-refractory advanced pancreatic cancer: A randomized, open-label, phase III trial (GRAPE trial).

TAS-118 (S-1 plus leucovorin) versus S-1 in gemcitabine-refractory advanced pancreatic cancer: A randomized, open-label, phase III trial (GRAPE trial).

Abstract Poster

Authors

null

Makoto Ueno

Division of Hepatobiliary and Pancreatic Medical Oncology, Kanagawa Cancer Center, Yokohama, Japan

Makoto Ueno , Tatsuya Ioka , Hideki Ueno , Joon Oh Park , Heung-Moon Chang , Naoki Sasahira , Masashi Kanai , Ik-Joo Chung , Masafumi Ikeda , Shoji Nakamori , Nobumasa Mizuno , Yasushi Omuro , Taketo Yamaguchi , Hiroki Hara , Kazuya Sugimori , Junji Furuse , Masahiro Takeuchi , Takuji Okusaka , Narikazu Boku , Ichinosuke Hyodo

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal (Noncolorectal) Cancer

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Pancreatic Cancer

Clinical Trial Registration Number

132172

Citation

J Clin Oncol 35, 2017 (suppl; abstr 4099)

DOI

10.1200/JCO.2017.35.15_suppl.4099

Abstract #

4099

Poster Bd #

91

Abstract Disclosures

Similar Posters

First Author: Benedikt Westphalen

First Author: Andrea Wang-Gillam

First Author: Derek B. Grose

First Author: Angela Lamarca